XML 111 R70.htm IDEA: XBRL DOCUMENT
v3.20.2

Business Combination (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K) | 12 Months Ended
--- | ---
Dec. 31, 2019
Brooklyn Immunotherapeutics, LLC [Member] |
Schedule of Purchase Price for Acquisition | The following table details the allocation of the purchase price for the acquisition of BITX:
Cash |  | $ | 250,296 |
Restricted cash |  |  | 86,000 |
Prepaid expenses and other current assets |  |  | 19,998 |
Security deposits and other assets |  |  | 379,331 |
Laboratory equipment |  |  | 69,597 |
In process research and development |  |  | 6,860,000 |
Accounts payable and accrued expenses |  |  | (4,528,969 | )
Loans payable |  |  | (410,000 | )
Loans payable, related parties |  |  | (1,500,000 | )
Net fair value assigned to assets acquired and liabilities assumed |  |  | 1,226,253 |
Goodwill |  |  | 2,043,747 |
Total |  | $ | 3,270,000 |

X
- Definition Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |